Marstacimab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain), DMC (Denmark) and HIRA (South Korea), among others, recommended or restricted marstacimab, while AOTMIT (Poland), CONITEC (Brazil) and NYE METODER (Norway) did not recommend it.
Every record falls within a 1.7-year window, 12 Dec 2024 to 6 Aug 2026 — a compressed review cycle.
No assessment is on file from HAS (France), PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 13 of 13 records date from 2023 or later.
3 distinct indication wordings are recorded for marstacimab by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess marstacimab, on 12 Dec 2024; HIRA (South Korea) did not open a file until 6 Aug 2026 — a moderate spread of 1.7 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 13 dated records fall in 2025 alone.
Restriction is doing real work here: 3 of 9 decisive outcomes narrowed marstacimab to a subgroup rather than accepting or refusing it outright, at HIRA (South Korea), NICE (England) and SMC (Scotland).
G-BA (Germany) is the only agency to have returned to marstacimab, recording 2 separate entries.
marstacimab has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for marstacimab reads 3 restricted, 3 not recommended, 3 no benefit and 3 recommended, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 21 Jul 2026 | Tratamento profilático para prevenir ou reduzir a frequência de episódios de sangramento em pacientes adultos e adolesce… | not incorporated | source |
| NYE METODER (Norway) | 17 May 2026 | Rutinemessig profylakse av blødningsepisoder hos pasienter som er 12 år og eldre, som veier minst 35 kg, og som har: - a… | not introduced | source |
| AOTMIT (Poland) | 20 Mar 2026 | programu lekowego B.15. „Zapobieganie krwawieniom u dzieci i dorosłych z hemofilią A i B (ICD-10: D66, D67) | not recommended | source |
| AIFA (Italy) | 27 Jan 2026 | Profilassi di routine degli episodi di sanguinamento in pazienti di età pari o superiore a 12 anni e di peso pari o supe… | innovative status not granted · reimbursed class A | source |
| SMC (Scotland) | 19 Jan 2026 | For routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with: severe haemophilia A (congenital factor VIII deficiency… | accepted (restricted) | source |
8 further decisions for marstacimab, across 7 agencies, are not shown here. They include the most recent record on file, 6 Aug 2026 from HIRA (South Korea); its outcome is in the subscriber dataset. They link to 8 further source documents.
Related molecules
- emicizumab — divergent outcome (restricted vs recommended) on a shared indication
- eltrombopag — same ATC class B02B — Antihemorrhagics
- romiplostim — same ATC class B02B — Antihemorrhagics
- avatrombopag — same ATC class B02B — Antihemorrhagics
- concizumab — same ATC class B02B — Antihemorrhagics
- etranacogene dezaparvovec — same ATC class B02B — Antihemorrhagics
Coverage: 13 decisions for marstacimab from 12 agencies, 2024 to 2026. Data to 7 Sep 2026. ATC class B02B — Antihemorrhagics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.